Evidence map›Paper›PMID 22415834›Full record

ArticleNature communications2012

Sensitivity control through attenuation of signal transfer efficiency by negative regulation of cellular signalling.

Yu Toyoshima, Hiroaki Kakuda, Kazuhiro A Fujita, Shinsuke Uda, Shinya Kuroda

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Nature communications, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 21 citations in OpenAlex.

  1. Finding new edges: systems approaches to MTOR signaling.Biochemical Society transactions · 2021
    Review
  2. Endothelial dysfunction due to selective insulin resistance in vascular endothelium: insights from mechanistic modeling.American journal of physiology. Endocrinology and metabolism · 2020 · on this map
    Article
  3. Article
  4. Article
  5. Article
  6. Understanding the mTOR signaling pathway via mathematical modeling.Wiley interdisciplinary reviews. Systems biology and medicine · 2017
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Yu ToyoshimaDepartment of Biophysics and Biochemistry, Graduate School of Science, University of Tokyo, Hongo 7-3-1, Bunkyo-ku, Tokyo 113-0033, Japan.
Hiroaki Kakuda
Kazuhiro A Fujita
Shinsuke Uda
Shinya Kuroda
The University of Tokyo · JPTokyo University of Science · JPJapan Science and Technology Agency · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sensitivity is one of the hallmarks of biological and pharmacological responses. However, the principle of controlling sensitivity remains unclear. Here we theoretically analyse a simple biochemical reaction and find that the signal transfer efficiency of the transient peak amplitude attenuates depending on the strength of negative regulation. We experimentally find that many signalling pathways in various cell lines, including the Akt and ERK pathways, can be approximated by simple biochemical reactions and that the same property of the attenuation of signal transfer efficiency was observed for such pathways. Because of this property, a downstream molecule should show higher sensitivity to an activator and lower sensitivity to an inhibitor than an upstream molecule. Indeed, we experimentally verify that S6, which lies downstream of Akt, shows lower sensitivity to an epidermal growth factor receptor inhibitor than Akt. Thus, cells can control downstream sensitivity through the attenuation of signal transfer efficiency by changing the expression level of negative regulators.

Indexed as

MAP Kinase Signaling System3T3 CellsAnimalsCell LineCell Line, TumorErbB ReceptorsExtracellular Signal-Regulated MAP KinasesHeLa CellsHumansLapatinibMiceModels, BiologicalProtein Kinase InhibitorsProto-Oncogene Proteins c-aktQuinazolinesRatsErbB ReceptorsExtracellular Signal-Regulated MAP KinasesLapatinibProtein Kinase InhibitorsProto-Oncogene Proteins c-aktQuinazolines

Identifiers

PMID22415834
OpenAlexW2026992340

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.